Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit

BACKGROUND: Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC) patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of trastuzumab according to the response to trastuzumab...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Cancer
Egile Nagusiak: Triulzi, Tiziana, Regondi, Viola, De Cecco, Loris, Cappelletti, Maria Rosa, Di Modica, Martina, Paolini, Biagio, Lollini, Pier Luigi, Di Cosimo, Serena, Sfondrini, Lucia, Generali, Daniele, Tagliabue, Elda
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6288086/
https://ncbi.nlm.nih.gov/pubmed/30478407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0318-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak